BiosanaPharma: first mAb produced via fully continuous biomanufacturing to the clinic

During the recent Bioprocess International Conference in Boston, Maarten Pennings, CTO at BiosanaPharma, gave a presentation entitled: “Integrated Continuous Bioprocessing: A Small Company Approach for a Phase I Clinical Trial Material Manufacturing Case Study.” Pennings said the company chose this mAb because the molecule has a validated biomarker and because competition for this biosimilar molecule was still low. Last February BiosanaPharma received approval to begin a Phase I clinical trial for a biosimilar version of omalizumab, the first monoclonal antibody (mAb) produced with a fully continuous biomanufacturing process.  Read more